Today Asymmetrex continues its efforts to bring more attention to the long-standing need for tissue stem cell counting in regenerative medicine. In a post on RegMedNet, the company contrasts the quantitative dosing precision required for pharmaceutical drug trials to the complete vacuum of quantitative dosing for tissue stem cells in regenerative medicine trials. Asymmetrex invites regenerative medicine companies and physicians’ trials group to evaluate the company’s new AlphaSTEM technology for counting tissue stem cells. Asymmetrex predicts that adoption of the technology in 2016 would have a major impact on the quality of stem cell medicine clinical trials.
Leave a Reply